beta
IA Trial Radar
Um estudo corresponde aos critérios do filtro
Visualização em cartões
Voltar à pesquisa

To Evaluate the Change in Glucose Parameters in Adult Patients With Type 1 or Type 2 Diabetes From Europe Using the iCan o3 CGM System for 60 Days Period (DETECT) 70 Dados de vida real

Recrutamento por convite
Os detalhes do estudo clínico estão disponíveis principalmente em inglês. No entanto, a IA Trial Radar pode ajudar! Basta clicar em 'Explicar o estudo' para visualizar e discutir as informações do estudo no idioma selecionado.
O estudo clínico NCT06904846 (DETECT) é um estudo intervencionista para Diabetes mellitus, Continuous Glucose Monitoring System. Seu status atual é: recrutamento por convite. O estudo começou em 23 de abril de 2025 e pretende incluir 70 participantes. Coordenado por Sinocare e deve ser concluído em 30 de junho de 2026. Essas informações foram atualizadas no ClinicalTrials.gov em 14 de janeiro de 2026.
Resumo
This study is a post-market, prospective, interventional, multicenter clinical trial designed to evaluate the impact of the iCan O3 Continuous Glucose Monitoring (CGM) System on glycemic control in adults with Type 1 (T1D) or Type 2 Diabetes (T2D). Coordinated by Prof. Dr. Christophe De Block at Universitair Ziekenhuis Antwerpen (UZA), Belgium, and sponsored by Changsha Sinocare Inc., the study aims to assess changes...Mostrar mais
Título oficial

Prospective Post-market Clinical Follow-up (PMCF) Study Aimed to Evaluate the Change in Glucometric Parameters in Adult Patients With Type 1 or Type 2 DiabETes From Europe Using the iCan o3 CGM SysTem for a 60-day Period

Condições médicas
Diabetes mellitusContinuous Glucose Monitoring System
Outros IDs do estudo
  • DETECT
  • NPI031-PMCFR-001
Número NCT
NCT06904846
Data de início (real)
2025-04-23
Última atualização postada
2026-01-14
Data de conclusão (estimada)
2026-06-30
Inscrição (estimada)
70
Tipo de estudo
Intervencionista
FASE
N/A
Status
Recrutamento por convite
Propósito principal
Tratamento
Alocação do design
N/A
Modelo de intervenção
Grupo único
Cegamento (Mascaramento)
Nenhum (Aberto)
Braços / Intervenções
Grupo de participantes/BraçoIntervenção/Tratamento
ExperimentalPatients with Type 1 diabetes (T1D) or Type 2 diabetes (T2D)
The start-up pathway is for all persons with T2D who are not being treated in another diabetes system. People with T2D in remission can also apply for the start-up pathway. The care pathway is for persons with T2D who are treated with Glucagon-like peptide-1 (GLP-1) analogues (injectable or pill) or 1 to 2 insulin injections/day. This pathway can also be initiated if treatment with blood sugar-lowering medication (pi...Mostrar mais
iCan o3 CGM Continuous Glucose Monitoring System
A continuous Glucose Monitoring System (CGM System) is a real-time, continuous glucose monitoring device indicated for the management of diabetes for adult persons (age 18 and older). It is intended to replace finger prick blood glucose testing for diabetes treatment decisions. The CGM System also shows trends and tracks patterns, and aids in the detection of episodes of hyperglycemia and hypoglycemia, facilitating b...Mostrar mais
Desfecho primário
Medida de desfechoDescrição da medidaPrazo
Improvement of Glycemic control
The increased percentage of Time in range (TIR) compare to the baseline period
60 days
Assistente de participação
Critérios de elegibilidade

Idades elegíveis
Adulto, Idoso
Idade mínima
18 Years
Sexos elegíveis
Todos
  1. Patient age is between 18 and 75 years old. Patient age is between 18 and 75 years old.
  2. Patient is clinically diagnosed with diabetes for at least 6 months (all treatment modalities are allowed).
  3. Patient has a Hemoglobin A1c (HbA1c) of > 7,5%.
  4. Patient is sensor naive.
  5. Patient is willing to wear the device on the abdomen for the whole study period.
  6. Patient has a stable (unchanged) treatment regimen for at least 3 months. "Stable treatment regimen" is considered no changes in prescribed number of insulin deliveries a day, and a change in total daily insulin dose of less than 10%. Patients currently taking glucagon-like peptide-1 (GLP1) analogs before the study can be included.
  7. Patient has a compatible smartphone.
  8. Patient shows sufficient skills using a smartphone and apps, as judged by the investigator.
  9. Patient and investigator signed and dated the informed consent form prior to first sensor placement.

  1. Patient was hospitalized because of hyperglycemia/ketoacidosis within the last 6 months.
  2. Patient was hospitalized because of hypoglycemia within the last 6 months.
  3. Patient has a condition which may predispose him/her to hypoglycemia including, but not limited to, thyroid disease which is not well controlled, adrenal insufficiency, high dose steroid use in recent past or planned during study, significant renal or liver disease.
  4. Patient has a planned magnetic resonance imaging (MRI), Computed Tomography (CT) scan or diathermic procedure during the period of sensor wear.
  5. Patient with a significant medical or psychiatric disorder, or use of a medication which will affect the application of the protocol judged by the investigator.
  6. Patient with cognitive difficulties that may impair the ability to follow the protocol judged by the investigator.
  7. Patient is critically ill.
  8. Patient has a coagulation disorder or takes heparin-like antiplatelet medication.
  9. Patient is pregnant or is intending to become pregnant during the study period.
  10. Patient does not take clinically acceptable contraception or does not practice abstinence.
  11. Patient has a history of skin adhesive tolerance issues in the area of sensor placement.
  12. Patient has abnormal skin at the anticipated glucose sensor insertion sites (excessive hair, burn, inflammation, infection, rash, and/or tattoo).
  13. Patient has any medical history of malignant melanoma or breast cancer.
  14. Patient has a medical history of any other cancers within the last five years except adequately treated basal cell or squamous carcinoma of the skin, or cervical carcinoma in-situ.
  15. Patient has a history of alcohol or drug abuse within the last year.
  16. Patient has a history of a seizure disorder.
  17. Patient has a medical history of stroke, transitory cerebral ischemia, myocardial infarction, unstable angina or heart failure with in the past 12 months.
  18. Patient is on dialysis.
  19. Patient is implanted with a pacemaker.
  20. Patient is currently being treated with drugs known to have significant interference with glucose metabolism, such as systemic corticosteroids, as judged by the investigator.
  21. Patient has a concomitant pathology that might cause edema at the insertion sites (such as heart failure, liver failure, kidney failure defined as estimated Glomerular Filtration Rate (eGFR) <30 mL/min \[stage ≥4\]).
  22. Patient underwent beta-cell transplantation.
  23. Patient is unable / unwilling to provide informed consent.
  24. Patient is unable to comply with the protocol or proposed study visits.
  25. Patient who is currently enrolled in another clinical study, or has recently participated in a clinical study, that could potentially interfere with the outcomes or introduce bias into the results of the current study (as determined by the investigator). This includes studies involving investigational drugs, medical devices, or other interventions that could impact the safety, efficacy, or scientific integrity of this study.
  26. Other reasons that require the investigator to exclude the patient from the study.
Sinocare logoSinocare
Archer Research logoArcher Research
Sem dados de contato.
1 Locais do estudo em 1 países
UZA ANTWERP UZA Dienst Endocrinologie, Antwerp, Belgium